Ir >>   
Uds: 0
Importe: 0,00
Tengo un usuario, deseo validarme - regístrate
  Buscar/Pesquisa        Búsqueda avanzada  
Herramienta de traducción gratuita de páginas web
Inicio/Iniciação
 > Libros de Medicina  > Hematología  > Leucemia  - Llámanos (+34) 913788918 ¡Gasto de envío gratis para pedidos superiores a 50€ (sin iva) en Península!
Chronic Myeloid Leukemia (Hematologic Malignancies)
Chronic Myeloid Leukemia (Hematologic Malignancies)
Edición/Edição:
Autores: Rudiger Hehlmann
Editorial:
ISBN: 9783319331973
Formato: Rústica/Paperback
Nº volumenes: 1 Páginas: 257
Año publicación/Ano de publicação: 2016
Disponibilidad/Disponibilidade: 15 días
Precio/Preço : 94,49 € 89,76 € (93,35€ iva incluído)
 (Sea el primero en opinar ) ¿Vas a pedir más de 5 productos? Escríbenos, te enviaremos presupuesto ajustado, envíanos mail

Cómpralos juntos y ahorra
Chronic Myeloid Leukemia (Hematologic Malignancies) Atlas de Hematología Clínica 5ª Ed.
· Chronic Myeloid Leukemia (Hematologic Malignancies) (Rudiger Hehlmann)
· Atlas de Hematología Clínica 5ª Ed. (Bernadette F. Rodak | Jacqueline H. Carr)
137,76 € 130,87 €
Descripción/Descrição
◾Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemia
◾Covers a wide range of management topics
◾Discusses prognostic aspects and early response prediction
◾Examines the changing face and cost of care

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon ¦Á in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.

R¨¹diger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany. Professor Hehlmann is past Chief of Medicine at Mannheim, past President of the German Society of Hematology and Oncology, past Dean of his faculty, and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is founder and chair of the German CML Study Group, of the German Competence Network on acute and chronic leukemias, and of the European LeukemiaNet. He is an honorary member of the Polish and German Societies for Hematology and honorary doctor of the University of Uppsala, Sweden. He has received various awards for leukemia research and interdisciplinary cooperation. His research interests focus on leukemia, in particular CML, on mechanisms of leukemogenesis, and on progression to blast crisis.


Lo más vendido este mes/Os mais vendidos este mês
Suscripciones
Si desea suscribirse a nuestros boletines gratuitos por favor regístrese como usuario.
Atención clientes
Para realizar sus pedidos o consultas relacionadas con productos llame al:
(+34)91 378 89 18





 

Acerca de los certificados SSL
Nosotros subscribimos Los Principios del código HONcode de la Fundación Salud en la Red Nosotros subscribimos los Principios del código HONcode. Compruébelo aquí.